Posts

Cellmid moves closer to evolis anti-hair loss patent in China

Cellmid moves closer to evolis anti-hair loss patent in China

Cellmid moves closer to evolis anti-hair loss patent in China

Cellmid Limited has announced its évolis® Chinese patent will soon be granted with the Chinese Patent Office issuing a notice of intention to grant the application protecting the technology.

The Chinese patent provides protection in the territory for hair therapy formulations comprising a class of small molecules called monoterpenoids, originally derived from botanical extracts.

The patent covers the fibroblast growth factor 5 (FGF5) technology and several ingredients adding value to the company’s asset portfolio and expires in December 2034.
Chinese distribution strategy

Granting of this patent is an important commercial milestone for the company’s Chinese product strategy for establishing and protecting évolis in China.

The company is expanding distribution into China following its cross-border e-commerce partnership with Aeon international, the Australian subsidiary of Chinese e-commerce company Habesul, which has over 30 years’ experience in international trade and distribution.

The permit will also add to Cellmid’s agreement with pharmaceutical company Fukangren to register the products with the state food and drug administration and sell the products in Chinese pharmacies and clinics.
The FGF5 technology

The method covered by this patent involves administering a topical formulation containing a monoterpenoid to inhibit the hair growth cycle regulatory protein FGF5.

Cellmid’s wholly owned subsidiary Advangen completed rigorous testing in 2017 which showed that several monoterpenoid compounds were potent inhibitors of FGF5, enabling hair follicles to maintain growth in the anagen phase.

Topical application of formulations containing key botanical extracts and FGF5- inhibiting monoterpenoids is central to Advangen’s évolis products against hair loss.

The monoterpenoids-alopecia patents are held by Advangen Limited and protect the formulation of and distinguish the évolis therapeutic and anti-aging hair care ranges from any other product on the market.

Cellmid moves closer to evolis anti-hair loss patent in China

Source

Previous Posts

Cellmid moves closer to evolis anti-hair loss patent in China

Cellmid moves closer to evolis anti-hair loss patent in China

Cellmid moves closer to evolis anti-hair loss patent in China

Cellmid Limited has announced its évolis® Chinese patent will soon be granted with the Chinese Patent Office issuing a notice of intention to grant the application protecting the technology.

The Chinese patent provides protection in the territory for hair therapy formulations comprising a class of small molecules called monoterpenoids, originally derived from botanical extracts.

The patent covers the fibroblast growth factor 5 (FGF5) technology and several ingredients adding value to the company’s asset portfolio and expires in December 2034.
Chinese distribution strategy

Granting of this patent is an important commercial milestone for the company’s Chinese product strategy for establishing and protecting évolis in China.

The company is expanding distribution into China following its cross-border e-commerce partnership with Aeon international, the Australian subsidiary of Chinese e-commerce company Habesul, which has over 30 years’ experience in international trade and distribution.

The permit will also add to Cellmid’s agreement with pharmaceutical company Fukangren to register the products with the state food and drug administration and sell the products in Chinese pharmacies and clinics.
The FGF5 technology

The method covered by this patent involves administering a topical formulation containing a monoterpenoid to inhibit the hair growth cycle regulatory protein FGF5.

Cellmid’s wholly owned subsidiary Advangen completed rigorous testing in 2017 which showed that several monoterpenoid compounds were potent inhibitors of FGF5, enabling hair follicles to maintain growth in the anagen phase.

Topical application of formulations containing key botanical extracts and FGF5- inhibiting monoterpenoids is central to Advangen’s évolis products against hair loss.

The monoterpenoids-alopecia patents are held by Advangen Limited and protect the formulation of and distinguish the évolis therapeutic and anti-aging hair care ranges from any other product on the market.

Cellmid moves closer to evolis anti-hair loss patent in China

Source

Previous Posts

évolis hair loss products

Cellmid makes move to sell hair loss products into China

Cellmid makes move to sell hair loss products into China

Cellmid Limited has signed a master supply agreement with YPB Group Ltd to market the company’s évolis hair loss products in China.

The agreement will see Cellmid utilise YPB’s CONNECT platform, which will help Cellmid connect with its Chinese customers.

This is part of a comprehensive strategy to enter the Chinese consumer health market with the company’s various brands of FGF5 inhibitor hair loss products.

YPB will supply Cellmid with QR labels to be applied to its products for two key reasons.

Firstly, it protects Cellmid’s product against counterfeits and fakes as consumers are able to use their mobile phone to scan the QR code to verify the product authenticity.

Secondly, the QR code becomes a point for data collection and communication with Cellmid’s Chinese customer base.

Gaining an in-depth knowledge of the customer

Mobile device scanning of the QR code launches a cascade of digital events that sees CONNECT capture and analyse data.

This data provides Cellmid with deep knowledge of its consumers and the capacity to develop personalised interactions with them.

Once that connection is established, CONNECT can then be used for a range of personalised education, marketing and promotional activities to enrich experiences and increase loyalty.

Chief executive expects return on investment

Maria Halasz, chief executive, said: “Access to the CONNECT platform is expected to be transformative for our consumer strategy in China.

“Knowing the customer behind each sale means that we can become partners in their hair health and provide tailored, personalised information and products to suit their individual needs.

“Together with our multilayered strategy to access the Chinese consumer market, the CONNECT platform is expected to improve our return on marketing investment significantly.”

évolis hair

September quarter sales reach $1.03 million

Cellmid has two business segments – consumer health and its midkine (MK) portfolio.

The consumer health segment currently sells hair growth products in Australia, Japan and the U.S, which were developed using FGF5 related intellectual property.

During the recent September quarter, the consumer health segment achieves sales of $1.03 million, up 4% on the prior corresponding quarter.

The majority of sales are generated in Japan and Cellmid also recently launched its lead revenue driving évolis hair loss products into the U.S. market.

Source